← Leaderboards
Andrew Jon Haak
Sanford Burnham Prebys Medical Discovery Institute
$2,107,274
Attributed
$3,036,508
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,036,508 · 3
By mechanism
R61$1,262,407 · 1
R01$1,178,040 · 1
R33$596,061 · 1
Top collaborators
- Susanne Heynen-Genel3 shared
Most similar at Sanford Burnham Prebys Medical Discovery Institute
Same institution · by research overlap
- Susanne Heynen-Genel$2,110,636
- Cosimo Commisso$11,152,767
Others in their field
Other Rising Stars on “Deposition”
- Frank A Provenzano · St. Joseph'S Hospital And Medical Center$8,533,907
- Brian J Lopresti · University Of Pittsburgh At Pittsburgh$6,934,890
- Erica Anderson$6,734,645
- Monica Cecilia Munoz-Torres · University Of Colorado Denver$5,306,335
- Pamela Lutsey · University Of Minnesota$4,596,906
- Lynne Wagenknecht · Wake Forest University Health Sciences$4,422,465
Research focus
DepositionInhibitorLungIn VivoPulmonary FibrosisMolecularEpithelial CellsFibrosisIdiopathic Pulmonary FibrosisIn VitroPathway InteractionsPhosphorylationRodent ModelSignal TransductionEndotheliumChronicFibroblastsExperimental StudyGenetic TranscriptionCellsEpitheliumCardiovascular SystemAgonistDopamine Receptor
Grant awards (5)
Targeting Senescence Specific Mechanisms of NF-κB Activation to Reverse Chronic Pulmonary Fibrosis$589,020
R01 · FY2025 · HL · contact PI
Optimization of fibroblast-selective inhibitors of YAP/TAZ as novel therapeutics for Pulmonary Fibrosis$596,061
R33 · FY2024 · HL
Targeting Senescence Specific Mechanisms of NF-κB Activation to Reverse Chronic Pulmonary Fibrosis$589,020
R01 · FY2024 · HL · contact PI
Optimization of fibroblast-selective inhibitors of YAP/TAZ as novel therapeutics for Pulmonary Fibrosis$618,908
R61 · FY2023 · HL
Optimization of fibroblast-selective inhibitors of YAP/TAZ as novel therapeutics for Pulmonary Fibrosis$643,499
R61 · FY2022 · HL